Piper Sandler analyst David Amsellem reiterates an Overweight rating on Supernus Pharmaceuticals with a $45 price target after conducting a survey of 25 psychiatrists who manage significant numbers of adult patients with ADHD. The feedback suggests that psychiatrists not only view Supernus’ Qelbree as a more reliable non-stimulant option relative to Strattera, but also view the product as a useful alternative to stimulants, the analyst tells investors in a research note. The firm says the survey points to "continued brisk expansion of the Qelbree volume footprint." It continues to believe that Qelbree peak U.S. sales potential approaching $500M are realistic. Piper views Supernus’ risk/reward profile as attractive at current share levels.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SUPN:
- Supernus to Participate in Two Upcoming Investor Conferences
- Supernus to Present at the Cowen 43rd Annual Health Care Conference
- Supernus reports Q4 diluted EPS 43c, consensus 68c
- Supernus Announces Fourth Quarter and Full Year 2022 Financial Results
- Supernus Enters Into $150 Million Credit Facility